
Tempus AI's business model is built around providing cutting-edge technology and data analytics to the healthcare industry. The company's focus is on accelerating the discovery and development of life-changing therapies.
Tempus AI's platform aggregates and analyzes vast amounts of clinical and molecular data to help researchers and clinicians make more informed decisions. This data-driven approach aims to improve patient outcomes and reduce the time it takes to bring new treatments to market.
Tempus AI's platform is used by leading research institutions, pharmaceutical companies, and healthcare providers to accelerate the development of new therapies. The company's technology has the potential to revolutionize the way we approach cancer treatment and other complex diseases.
A fresh viewpoint: Ai Based Ecommerce Platform
Financial Performance
Tempus AI's revenue reached $693.40 million in 2024, a 30.38% increase from the previous year's $531.82 million.
The company's losses were substantial, at -$746.33 million, a 180.6% increase from 2023.
Here are some key financial metrics for Tempus AI:
- Total Cash (mrq): $291.31M
- Total Debt/Equity (mrq): 275.63%
- Levered Free Cash Flow (ttm): $18.93M
Wall Street expects a loss of 20 cents per share and $203.12 million in revenues for Tempus AI's fourth-quarter earnings.
Funding History

Tempus has a significant funding history, with over $10 billion in multiple rounds of private financing from 2015 to 2023.
The company has attracted notable investors, including New Enterprise Associates (NEA) and Revolution Growth, which co-led the C-round financing in 2017, securing $130 million in funding.
Tempus' valuation reached $50 billion in 2020, with a $1 billion financing round backed by prominent investors like Baillie Gifford, Franklin Templeton, Novo Holdings, NEA, and T. Rowe Price.
In 2022, Tempus received $275 million in funding from Ares Management through a combination of equity and debt.
Google's venture arm invested $2 billion in Tempus in 2020, valuing the company at $81 billion, with the aim of supporting its expansion into areas like infectious diseases, depression, and heart disease.
SoftBank invested around $2 billion in Tempus during the G-round in 2024, just before its IPO.
Tempus' pre-IPO investors include notable venture capital firms and institutions like NEA, Revolution, Baillie Gifford, Franklin Templeton, T. Rowe Price, Novo, Google, and SoftBank.
For more insights, see: Perplexity Ai Investors
Financial Performance
Tempus AI's revenue jumped 30.38% in 2024 to $693.40 million.
This significant increase is a testament to the company's growing success in the healthcare AI industry.
In 2024, Tempus AI reported a loss of -$746.33 million, a staggering 180.6% more than the previous year.
Their financial performance is a complex mix of growth and challenges, but one thing is clear: they're making waves in the industry.
Here's a breakdown of their key financial metrics:
Wall Street expects Tempus AI to report a loss of 20 cents per share and $203.12 million in revenues for Q4 2024.
Analysts are optimistic about the company's future prospects, with an average rating of "Buy" and a 12-month stock price forecast of $60.4.
Stock Performance
Tempus AI's stock has seen significant growth, with a 45% surge in a week after the company announced the launch of its AI app – Olivia.
The company's stock was listed on June 14, 2024, and has since delivered impressive returns.
Tempus AI has outperformed the broader market and AI-themed stocks with an 82% YTD return, making it a standout performer amidst market volatility.
Business Mode
Tempus AI's business model is built around three core product lines: genomics, data, and applications. These lines work together to create a sustainable ecosystem that drives value.
Tempus focuses on creating a comprehensive ecosystem by concentrating on these three product lines. The company leverages its CAP-certified and CLIA-certified laboratory to perform high-throughput genomic sequencing, primarily in the oncology field, providing detailed reports and AI-driven insights to help doctors make personalized treatment decisions.
Tempus generates revenue from its "genomics" business on a per-test basis. At the same time, the company uses the vast amounts of data collected from these tests, electronic health records, and imaging to provide data-driven services to third parties. The "data and services" business includes providing de-identified clinical and molecular data, as well as analysis tools, to pharmaceutical and biotech companies for research, drug development, and clinical trials.
Tempus has established strategic partnerships with major players in the pharmaceutical industry, such as AstraZeneca and GlaxoSmithKline, through multi-year data licensing agreements. These partnerships demonstrate the value of Tempus' database and AI models to global pharmaceutical leaders.
On a similar theme: What Does Ai Stand for in Business
Tempus' core revenue comes from its genomics and diagnostic testing services. In the oncology field, the company sequences tumor DNA and RNA from patient biopsy samples to identify mutations and recommend the best treatments or clinical trials using AI algorithms.
Tempus has expanded its testing menu beyond oncology to offer pharmacogenomics tests, such as Tempus nP, which helps predict patient responses to antidepressants and ADHD medications. The company is also exploring AI-enhanced cardiovascular disease diagnosis.
Here are some key products and services under Tempus' business model:
- Hub: A platform that integrates with doctors' workflows, enabling them to order lab tests, track results, and develop treatment plans.
- Its One: An AI assistant for healthcare providers and researchers to quickly gain insights.
- Lens: A tool for life science researchers to interact with de-identified data sets.
- Link: A clinical trial matching and registration software for tumor medical institutions.
- Olivia: A patient-centric AI-powered health assistant that integrates medical data and provides actionable insights.
Medical Stock Soars 35% on Tuesday
Tempus AI (TEM) stock had its best day on record on Tuesday after the medical tech company launched an AI-powered health concierge.
The launch of this new feature likely contributed to the stock's significant surge, but it wasn't the only factor - former House Speaker Nancy Pelosi revealed she's bet on the stock, which may have also influenced investors' decisions.

Tempus AI's stock price increase of 35% on Tuesday is a notable achievement, especially considering the volatility of the market.
The company's innovative approach to healthcare technology is certainly paying off, with TEM stock delivering an impressive 82% YTD return.
Tempus AI has been making waves in the industry with its acquisition of Ambry Genetics, which may have also contributed to the stock's recent success.
Despite the challenges in US healthcare reimbursement, Tempus AI's leading AI-enabled diagnostic platform has been a game-changer for the company.
Valuation and Profitability
Tempus AI 股票 offers a unique perspective on valuation and profitability, making it a fascinating topic to explore.
The Price/Earnings (Normalized) ratio for TEM is not available, but for 603122 and 688468, it stands at 71.44 and 26.91 respectively.
A closer look at the Price/Book Value ratio reveals that TEM has a significantly higher ratio of 200.01 compared to 603122 and 688468, which are 2.61 and 2.34 respectively.
The Price/Sales ratio for TEM is 12.02, while for 603122 and 688468, it is 2.97 and 7.33 respectively.
The Price/Cash Flow ratio for TEM is not available, but for 603122 and 688468, it stands at 46.38 and 17.66 respectively.
Here's a comparison of the valuation metrics for TEM, 603122, and 688468:
The Return on Assets (Normalized) ratio for TEM is -24.90%, while for 603122 and 688468, it is 2.00% and 6.26% respectively.
Return on Equity (Normalized) is not available for TEM, but for 603122 and 688468, it stands at 2.54% and 8.17% respectively.
Return on Invested Capital (Normalized) is also not available for TEM, but for 603122 and 688468, it is 2.18% and 6.71% respectively.
A key takeaway from the profitability metrics is that TEM's Return on Assets (Normalized) is significantly lower than that of 603122 and 688468.
Here's a comparison of the profitability metrics for TEM, 603122, and 688468:
The Market Cap for Tempus AI 股票 is 15.51B, making it a significant player in the market.
Healthcare Focus
Tempus AI is a healthcare technology company that operates as a healthcare information services provider. It offers next-generation sequencing diagnostics, polymerase chain reaction profiling, molecular genotyping, and other anatomic and molecular pathology testing to healthcare providers.
Tempus AI's product lines work in concert with one another, creating a pinwheel effect as they generate data, making it more valuable over time. This approach enables the company to provide a suite of analytical services to pharmaceutical and biotechnology companies.
The company has a strategic collaboration agreement with AstraZeneca and Pathos AI, Inc. to develop therapeutic programs in oncology. Tempus AI has also launched its 'AI-enabled personal health concierge app' called olivia, which aims to advance precision medicine and patient care.
You might like: Jio Financial Services
Healthcare Promise
Tempus AI is a healthcare technology company that's making waves with its AI-driven approach to precision medicine and patient care. They've developed a platform that combines genomic and clinical data with AI to create personalized treatments and diagnostics.
Their product lines work in concert with each other, creating a pinwheel effect that generates more valuable data over time. This is a game-changer in the healthcare industry, where data is key to making informed decisions.
Tempus AI offers a range of services, including next-generation sequencing diagnostics, molecular genotyping, and clinical trial matching. They've also developed a suite of algorithmic tests in oncology, which is a significant step forward in cancer treatment.
The company has a strategic collaboration agreement with AstraZeneca and Pathos AI to develop therapeutic programs in oncology. This partnership is a testament to the potential of AI in healthcare.
Tempus AI's platform, Hub, is a desktop and mobile platform for ordering, managing, and receiving tests and patient results. This makes it easier for healthcare providers to access the information they need to make informed decisions.
Their Insights product is a license library of linked clinical, molecular, and imaging de-identified data. This is a valuable resource for researchers and scientists who need access to large datasets to analyze and understand complex health issues.
Launch of Olivia Personal Health Concierge App
Tempus AI, Inc. has launched olivia, an AI-enabled Personal Health Concierge App for patients.
The app is designed to advance precision medicine and patient care.
Tempus AI is a technology company that leads the adoption of AI in healthcare.
The launch of olivia marks a significant milestone for the company.
Competitors and Market
TEM's competitors are part of the Technology Services sector and Packaged Software group, indicating a strong presence in the industry.
TEM's market capitalization falls within the large capitalization category, with a market cap of $16.75B, placing it between $10 billion and $200 billion.
This significant market presence suggests TEM is a major player in the industry, with competitors that are also well-established in the Technology Services sector and Packaged Software group.
Suggestion: Pra Group Stock
Tem Competitors
TEM's competitors are included in the Technology Services sector and Packaged Software group. This classification helps us understand the market landscape TEM operates in.
TEM has a large market capitalization of $16.75 billion, which falls into the large capitalization category. This means TEM is considered a significant player in the market.
To give you a better idea of TEM's market position, here are some key facts about its competitors:
- Market cap: $16.75B
- Large capitalization category
Competitive Advantage
A competitive advantage is what sets a business apart from its competitors, making it more attractive to customers and ultimately driving sales and revenue. According to our analysis, a company's market share is the key indicator of its competitive advantage.
Having a larger market share than its competitors gives a business a significant edge in the market. For example, in the market for online shopping, Amazon has a market share of over 30%, significantly higher than its closest competitor.
This market share is a result of Amazon's ability to offer a wide range of products, fast and reliable shipping, and a user-friendly interface. These factors combined have created a loyal customer base for Amazon.
To achieve a competitive advantage, businesses must focus on identifying and meeting the needs of their target market. By doing so, they can differentiate themselves from their competitors and establish a strong presence in the market.
For another approach, see: Jeff Bezos Has Sold 14 Million Shares of Amazon Stock
Events and Conferences
Tempus AI, Inc. is a technology company that leads the adoption of AI to advance precision medicine and patient care. They are listed on the NASDAQ as TEM.
Tempus AI has participated in various conferences and events, including the TD Cowen's 45th Annual Health Care Conference and the Morgan Stanley Technology, Media and Telecom Conference.
Present at TD Cowen's 45th Annual Health Care Conference
Tempus AI, Inc. will present at the TD Cowen 45th Annual Health Care Conference.
This conference is a significant event in the healthcare industry, and we're excited to see Tempus AI, Inc. take part.
The conference will be held in Chicago, a city known for its vibrant healthcare scene.
Tempus AI, Inc. is a technology company leading the adoption of AI to advance precision medicine and patient care.
They've made a name for themselves in the industry, and it's no surprise they're presenting at this prestigious conference.
Tempus AI, Inc. is listed on the NASDAQ stock exchange under the ticker symbol TEM.
Ares Management expands debt facilities to $560M

Ares Management recently expanded its debt facilities to a significant $560 million.
This move was announced through a press release, which was distributed by Business Wire.
Ares Credit funds served as the administrative agent for the debt facilities.
Curious to learn more? Check out: Is Preferred Shares Debt or Equity
News and Updates
Tempus AI's stock price surged 45% in a week after the company announced the launch of its AI app – Olivia.
The company's stock, TEM, was listed on June 14, 2024.
Tempus AI is a healthcare technology company.
The launch of Olivia marked a significant milestone for the company.
Investment Advice
If you're considering investing in Tempus AI stock, keep in mind that the price has rebounded this year due to increased demand for artificial intelligence solutions.
The stock price jumped to $61 after the company completed its acquisition of Ambry Genetics, a significant move that highlights the company's growing capabilities.
Before making a decision, it's essential to weigh the pros and cons of investing in Tempus AI stock, considering the current market trends and the company's future prospects.
Is It a Good Buy?
Investing in Tempus AI's stock can be a bit of a gamble, but it's worth considering its recent performance. The stock price has rebounded this year due to increased demand for artificial intelligence solutions.
Tempus AI's TEM stock jumped to $61 after completing its acquisition of Ambry Genetics, indicating a potential for growth. This acquisition could lead to new opportunities and revenue streams for the company.
However, the stock price is not cheap, and investors should be cautious about its valuation. The rebound in stock price is largely driven by the demand for AI solutions, which may not be sustainable in the long term.
Despite this, Tempus AI's stock could still be a good buy for investors who are willing to take on some risk. The company's recent performance and acquisition of Ambry Genetics suggest that it's on the right track.
You might like: Tmtg Stock Performance Inauguration
In Vogue, Consider Waiting
Tempus AI has delivered an 82% YTD return, outperforming the broader market and AI-themed stocks amidst market volatility.

Investors may want to consider waiting for a retracement before investing in Tempus AI, given its impressive recent performance.
Tempus AI closed the acquisition of Ambry Genetics, which could be a major factor in its success.
However, this rapid growth may be a sign of a potential bubble, making it a good idea to wait for a cooldown.
The company's AI-enabled diagnostic platform is a game-changer in the healthcare industry, but it's still a high-risk investment due to challenges in US healthcare reimbursement.
Featured Images: pexels.com


